Product Information
COSENTYX 150 MG/ML SYRINGE is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $7879.8111 per ML under NDC 00078063997. Its NADAC has been published 102 times since Oct 23, 2024.
Strength
150 mg/mL
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078063997
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
SECUKINUMABApproval Type
Biologic (BLA)
FDA Application
BLA125504On Market Since
1/21/2015
Pharmacological Classes
Price Statistics
The NADAC for COSENTYX 150 MG/ML SYRINGE has been published 102 times since Oct 23, 2024, and over the history we have for it it has risen 9.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7879.8111 per ML |
|---|---|
| All-time high | $7923.3134 (Jul 15, 2026) |
| All-time low | $7204.2657 (Nov 20, 2024) |
| 52-week high | $7923.3134 |
| 52-week low | $7388.0143 |
| Median price | $7422.9010 |
| Average price | $7570.3510 |
| Largest weekly change | +7.0% (Jan 14, 2026) |
| Weeks tracked | 102 |
| Tracking since | Oct 23, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 50% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
secukinumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Interleukin-17A Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of COSENTYX 150 MG/ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for COSENTYX 150 MG/ML SYRINGE, manufactured by Novartis Pharmaceuticals Corporation, is $7879.8111 per ML (NDC 00078063997), effective Sep 30, 2026.
How has the price of COSENTYX 150 MG/ML SYRINGE changed over time?
Over the history we have for it, the NADAC for COSENTYX 150 MG/ML SYRINGE has risen 9.2%. It has been tracked across 102 weekly CMS publications since Oct 23, 2024.
What are the highest and lowest recorded NADAC prices for COSENTYX 150 MG/ML SYRINGE?
Since Oct 23, 2024, the NADAC for COSENTYX 150 MG/ML SYRINGE has ranged from a low of $7204.2657 (Nov 20, 2024) to a high of $7923.3134 (Jul 15, 2026), with a median of $7422.9010 per ML.
Are there cheaper alternatives to COSENTYX 150 MG/ML SYRINGE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, COSENTYX (150 MG/ML) 300 MG DOSE-2 SYRINGES, is $3924.3531 per ML — about 50% below COSENTYX 150 MG/ML SYRINGE.
Who manufactures COSENTYX 150 MG/ML SYRINGE?
COSENTYX 150 MG/ML SYRINGE (NDC 00078063997) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.